RU2016103067A - Улучшенные аминокислотные последовательности, направленные против респираторно-синцитиального вируса человека (hrsv), и полипептиды, включающие такие последовательности, для профилактики и/или лечения инфекций дыхательных путей - Google Patents
Улучшенные аминокислотные последовательности, направленные против респираторно-синцитиального вируса человека (hrsv), и полипептиды, включающие такие последовательности, для профилактики и/или лечения инфекций дыхательных путей Download PDFInfo
- Publication number
- RU2016103067A RU2016103067A RU2016103067A RU2016103067A RU2016103067A RU 2016103067 A RU2016103067 A RU 2016103067A RU 2016103067 A RU2016103067 A RU 2016103067A RU 2016103067 A RU2016103067 A RU 2016103067A RU 2016103067 A RU2016103067 A RU 2016103067A
- Authority
- RU
- Russia
- Prior art keywords
- ile20leu
- gln108leu
- ala14pro
- glu1asp
- single variable
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 35
- 229920001184 polypeptide Polymers 0.000 title claims 34
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 34
- 150000001413 amino acids Chemical group 0.000 title claims 12
- 230000002265 prevention Effects 0.000 title 2
- 241000282414 Homo sapiens Species 0.000 title 1
- 241000711920 Human orthopneumovirus Species 0.000 title 1
- 241000700605 Viruses Species 0.000 title 1
- 230000001976 improved effect Effects 0.000 title 1
- 102220612213 Calcyclin-binding protein_E1D_mutation Human genes 0.000 claims 18
- 102220597331 Coiled-coil domain-containing protein 144A_Q108L_mutation Human genes 0.000 claims 18
- 102200133317 rs869025586 Human genes 0.000 claims 18
- 102220463950 rs7782939 Human genes 0.000 claims 16
- 102220138536 rs146905561 Human genes 0.000 claims 10
- 102200007401 rs3755955 Human genes 0.000 claims 10
- 102220571078 Growth arrest and DNA damage-inducible protein GADD45 gamma_A83R_mutation Human genes 0.000 claims 9
- 235000001014 amino acid Nutrition 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 5
- 101710160621 Fusion glycoprotein F0 Proteins 0.000 claims 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 235000003704 aspartic acid Nutrition 0.000 claims 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 3
- 210000004072 lung Anatomy 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 102220578068 ATPase MORC2_G78L_mutation Human genes 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 2
- 102220570985 Uncharacterized protein C7orf57_A74S_mutation Human genes 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102200092858 rs36084266 Human genes 0.000 claims 2
- 102220011971 rs397515737 Human genes 0.000 claims 2
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000037656 Respiratory Sounds Diseases 0.000 claims 1
- 206010057190 Respiratory tract infections Diseases 0.000 claims 1
- 206010042241 Stridor Diseases 0.000 claims 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- 108700023453 human respiratory syncytial virus F Proteins 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 102200043501 rs1800450 Human genes 0.000 claims 1
- 208000013220 shortness of breath Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18439609P | 2009-06-05 | 2009-06-05 | |
US61/184,396 | 2009-06-05 | ||
US26501409P | 2009-11-30 | 2009-11-30 | |
US61/265,014 | 2009-11-30 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011153239/10A Division RU2577134C2 (ru) | 2009-06-05 | 2010-06-07 | Улучшенные аминокислотные последовательности, направленные против респираторно-синцитиального вируса человека (hrsv), и полипептиды, включающие такие последовательности, для профилактики и/или лечения инфекций дыхательных путей |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2016103067A true RU2016103067A (ru) | 2018-11-20 |
RU2016103067A3 RU2016103067A3 (fr) | 2019-08-08 |
Family
ID=42333502
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016103067A RU2016103067A (ru) | 2009-06-05 | 2010-06-07 | Улучшенные аминокислотные последовательности, направленные против респираторно-синцитиального вируса человека (hrsv), и полипептиды, включающие такие последовательности, для профилактики и/или лечения инфекций дыхательных путей |
RU2011153239/10A RU2577134C2 (ru) | 2009-06-05 | 2010-06-07 | Улучшенные аминокислотные последовательности, направленные против респираторно-синцитиального вируса человека (hrsv), и полипептиды, включающие такие последовательности, для профилактики и/или лечения инфекций дыхательных путей |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011153239/10A RU2577134C2 (ru) | 2009-06-05 | 2010-06-07 | Улучшенные аминокислотные последовательности, направленные против респираторно-синцитиального вируса человека (hrsv), и полипептиды, включающие такие последовательности, для профилактики и/или лечения инфекций дыхательных путей |
Country Status (25)
Country | Link |
---|---|
US (3) | US8945567B2 (fr) |
EP (2) | EP2438087B1 (fr) |
JP (2) | JP6081196B2 (fr) |
KR (1) | KR101852204B1 (fr) |
CN (2) | CN102459332B (fr) |
AU (1) | AU2010255638B2 (fr) |
BR (1) | BRPI1010830A2 (fr) |
CA (1) | CA2764398A1 (fr) |
CY (1) | CY1119265T1 (fr) |
DK (1) | DK2438087T3 (fr) |
ES (1) | ES2643034T3 (fr) |
HR (1) | HRP20171194T1 (fr) |
HU (1) | HUE035773T2 (fr) |
IL (1) | IL216341A0 (fr) |
LT (1) | LT2438087T (fr) |
MX (1) | MX340541B (fr) |
NZ (1) | NZ597314A (fr) |
PH (1) | PH12019500644A1 (fr) |
PL (1) | PL2438087T3 (fr) |
PT (1) | PT2438087T (fr) |
RU (2) | RU2016103067A (fr) |
SG (1) | SG176095A1 (fr) |
SI (1) | SI2438087T1 (fr) |
WO (1) | WO2010139808A2 (fr) |
ZA (1) | ZA201108892B (fr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2285408T1 (sl) | 2008-06-05 | 2019-02-28 | Ablynx N.V. | Aminokislinska zaporedja usmerjena proti proteinom ovojnicam virusa in polipeptidi, ki zaporedja vsebujejo za zdravljenje virusnih bolezni |
RU2016103067A (ru) | 2009-06-05 | 2018-11-20 | Аблинкс Нв | Улучшенные аминокислотные последовательности, направленные против респираторно-синцитиального вируса человека (hrsv), и полипептиды, включающие такие последовательности, для профилактики и/или лечения инфекций дыхательных путей |
US9644022B2 (en) | 2009-11-30 | 2017-05-09 | Ablynx N.V. | Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
US8962807B2 (en) | 2009-12-14 | 2015-02-24 | Ablynx N.V. | Single variable domain antibodies against OX40L, constructs and therapeutic use |
PL2533761T3 (pl) | 2010-02-11 | 2019-09-30 | Ablynx N.V. | Sposoby i kompozycje do wytwarzania aerozoli |
WO2012056000A1 (fr) | 2010-10-29 | 2012-05-03 | Ablynx Nv | Procédé de production de domaines variables uniques d'immunoglobuline |
EP2707382B1 (fr) | 2011-05-09 | 2019-07-17 | Ablynx NV | Procédé pour la production de domaines variables uniques d'immunoglobuline |
US11339208B1 (en) | 2012-05-31 | 2022-05-24 | United States Of America As Represented By The Secretary Of The Air Force | Camelidae single-domain antibodies against Yersinia pestis and methods of use |
SI2968520T1 (sl) | 2013-03-14 | 2022-01-31 | Macrogenics, Inc. | Bispecifične molekule, ki so imunoreaktivne z imunskimi efektorskimi celicami, ki izražajo aktivacijski receptor |
JP6485817B2 (ja) | 2013-08-21 | 2019-03-20 | ヤンセン バイオファーマ インク. | 抗ウイルス化合物 |
WO2016022464A1 (fr) * | 2014-08-05 | 2016-02-11 | Alios Biopharma, Inc. | Polythérapie pour traiter un paramyxovirus |
AU2015323860B2 (en) | 2014-09-29 | 2021-05-27 | Duke University | Bispecific molecules comprising an HIV-1 envelope targeting arm |
KR102364212B1 (ko) | 2014-10-10 | 2022-02-17 | 아블린쓰 엔.브이. | 호흡기 질병들의 에어로졸 치료에 사용하기 위한 흡입 디바이스 |
AU2015329936A1 (en) * | 2014-10-10 | 2017-04-20 | Ablynx N.V. | Methods of treating RSV infections |
MA41614A (fr) | 2015-02-25 | 2018-01-02 | Alios Biopharma Inc | Composés antiviraux |
EP3313432A1 (fr) * | 2015-06-18 | 2018-05-02 | VIB vzw | Anticorps à domaine variable unique d'immunoglobuline contre la protéine f de pré-fusion de rsv |
EP3124042A1 (fr) * | 2015-07-28 | 2017-02-01 | VIB, vzw | Anticorps à domaine variable unique contre la protéine f prefusion du virus respiratoire syncytial (rsv) |
CN109311968A (zh) | 2016-05-02 | 2019-02-05 | 埃博灵克斯股份有限公司 | 治疗rsv感染 |
SG11201811280QA (en) | 2016-06-23 | 2019-01-30 | Ablynx Nv | Improved pharmacokinetic assays for immunoglobulin single variable domains |
CN106279410B (zh) * | 2016-09-29 | 2019-08-20 | 华南理工大学 | 一种二型登革热病毒ns1蛋白多价纳米抗体及制备方法 |
JP7265984B2 (ja) | 2016-10-21 | 2023-04-27 | アディマブ, エルエルシー | 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法 |
IL303833A (en) | 2016-10-21 | 2023-08-01 | Adimab Llc | Respiratory syncytial virus antibodies and methods for their production and use |
JP2020503843A (ja) | 2016-10-21 | 2020-02-06 | アディマブ, エルエルシー | 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法 |
WO2018099968A1 (fr) | 2016-11-29 | 2018-06-07 | Ablynx N.V. | Traitement d'une infection par le virus respiratoire syncytial (vrs) |
WO2019075433A1 (fr) * | 2017-10-13 | 2019-04-18 | Adimab, Llc | Anticorps contre le virus respiratoire syncytial et méthodes pour leurs génération et utilisation |
JP7123607B2 (ja) * | 2018-04-09 | 2022-08-23 | シャープ株式会社 | ユーザ装置、制御装置、及び通信制御方法 |
CA3134258A1 (fr) | 2019-04-10 | 2020-10-15 | Regeneron Pharmaceuticals, Inc. | Anticorps humains qui se lient au ret et leurs procedes d'utilisation |
CN111748571B (zh) * | 2019-10-11 | 2022-05-03 | 浙江禾霖生物科技有限公司 | 一种将枯草芽孢杆菌工程化为生产纳米抗体的多功能稳定平台的方法 |
IL293282A (en) | 2019-11-25 | 2022-07-01 | Mabloc Llc | Yellow fever antiviral antibodies and methods of making and using them |
US20210230248A1 (en) * | 2020-01-25 | 2021-07-29 | Jun Chen | Multivalent pharmacophores for high avidity and overexpressed-target specific binding and uses thereof |
CN116693673B (zh) * | 2023-07-26 | 2023-10-20 | 中国人民解放军军事科学院军事医学研究院 | 广谱抗SARS和SARS-CoV-2的纳米抗体、多价纳米抗体及其应用 |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1120945A (en) | 1964-08-11 | 1968-07-24 | Fisons Pharmaceuticals Ltd | Applicator in combination with a pressurised aerosol dispensing container |
EP0397834B1 (fr) | 1988-10-28 | 2000-02-02 | Genentech, Inc. | Procede d'identification de domaines actifs et de residus d'acides amines dans des polypeptides et des vaiantes d'hormones |
WO1990005144A1 (fr) | 1988-11-11 | 1990-05-17 | Medical Research Council | Ligands a domaine unique, recepteurs comprenant lesdits ligands, procedes pour leur production, et emploi desdits ligands et recepteurs |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
EP0527809B1 (fr) | 1990-04-05 | 1995-08-16 | CREA, Roberto | Mutagenese "traversante" |
EP0605522B1 (fr) | 1991-09-23 | 1999-06-23 | Medical Research Council | Méthodes de production d'anticorps humanisés |
DE69334095T2 (de) | 1992-07-17 | 2007-04-12 | Dana-Farber Cancer Institute, Boston | Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen |
DK1589107T3 (da) | 1992-08-21 | 2010-04-26 | Univ Bruxelles | Immonuglobuliner uden lette kæder |
WO1994029469A2 (fr) | 1993-06-07 | 1994-12-22 | Vical Incorporated | Plasmides adequats pour une therapie genique |
DK0702721T3 (da) | 1993-06-09 | 2001-05-21 | Unilever Nv | Fremgangsmåde til fremstilling af fusionsproteiner, der omfatter ScFv fragmenter, ved hjælp af en transformeret skimmelsvamp |
US6091639A (en) | 1993-08-27 | 2000-07-18 | Kabushiki Kaisha Toshiba | Non-volatile semiconductor memory device and data programming method |
KR960705209A (ko) | 1993-09-10 | 1996-10-09 | 잭 엠. 그랜노위츠 | 녹색 형광 단백의 용도 |
WO1995021191A1 (fr) | 1994-02-04 | 1995-08-10 | William Ward | Indicateur bioluminescent fonde sur l'expression d'un gene codant pour une proteine modifiee a fluorescence verte |
WO1995022618A1 (fr) | 1994-02-22 | 1995-08-24 | Dana-Farber Cancer Institute | Systeme de liberation d'acide nucleique, son procede de synthese et ses utilisations |
US5625048A (en) | 1994-11-10 | 1997-04-29 | The Regents Of The University Of California | Modified green fluorescent proteins |
EP0739981A1 (fr) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire |
US5693492A (en) | 1995-05-05 | 1997-12-02 | Merck & Co., Inc. | DNA encoding glutamate gated chloride channels |
US5811524A (en) * | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
EP0833907A1 (fr) | 1995-06-23 | 1998-04-08 | President And Fellows Of Harvard College | Regulation de la transcription de genes codant des recepteurs du facteur de croissance endotheliale vasculaire |
ATE184613T1 (de) | 1995-09-22 | 1999-10-15 | Novo Nordisk As | Varianten des grünen fluoreszenzproteins, gfp |
US6027881A (en) | 1996-05-08 | 2000-02-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence |
US6020182A (en) * | 1996-07-12 | 2000-02-01 | Connaught Laboratories Limited | Subunit respiratory syncytial virus vaccine preparation |
US6124128A (en) | 1996-08-16 | 2000-09-26 | The Regents Of The University Of California | Long wavelength engineered fluorescent proteins |
EP0977590A4 (fr) * | 1996-11-01 | 2001-03-14 | Smithkline Beecham Corp | Anticorps monoclonaux humains |
WO1998021355A1 (fr) | 1996-11-15 | 1998-05-22 | Life Technologies, Inc. | Mutants de la proteine fluorescente verte |
WO1998022141A2 (fr) | 1996-11-19 | 1998-05-28 | Sangstat Medical Corporation | Effets renforces pour therapeutique associee a l'haptene |
US7122636B1 (en) | 1997-02-21 | 2006-10-17 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
FR2766826B1 (fr) | 1997-08-04 | 2001-05-18 | Pasteur Institut | Vecteurs derives d'anticorps pour le transfert de substances dans les cellules |
KR20010034512A (ko) | 1998-02-19 | 2001-04-25 | 베렌슨, 론 | 림프구 활성화 조절을 위한 조성물 및 그 방법 |
GB9824632D0 (en) | 1998-11-10 | 1999-01-06 | Celltech Therapeutics Ltd | Biological compounds |
CA2361678A1 (fr) | 1999-02-05 | 2000-08-10 | Rijksuniversiteit Leiden | Methode de modulation de la biosynthese de metabolite dans des cellules recombinees |
CA2370351A1 (fr) | 1999-04-22 | 2000-11-02 | Unilever Plc | Inhibition d'une infection virale au moyen de proteines de liaison a l'antigene monovalentes |
AR030019A1 (es) | 1999-05-18 | 2003-08-13 | Smithkline Beecham Corp | Anticuerpos monoclonales humanos y fragmentos funcionales del mismo, un procedimiento para su produccion, composiciones farmaceuticas que los comprenden, una molecula aislada de acido nucleico, un plasmido recombinante, una celula hospedante y el uso de dichos anticuerpos para la manufactura de un m |
AU6322900A (en) | 1999-08-02 | 2001-02-19 | Keygene N.V. | Method for generating resistance against cgmmv in plants, genetic constructs for use in said method, and cgmmv-resistant plants obtained via said method |
GB9922124D0 (en) | 1999-09-17 | 1999-11-17 | Pfizer Ltd | Phosphodiesterase enzymes |
US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
DE19955408A1 (de) | 1999-11-18 | 2001-05-23 | Bayer Ag | GABA-B-Rezeptoren |
EP1240337B1 (fr) | 1999-12-24 | 2006-08-23 | Genentech, Inc. | Methodes et compositions permettant de prolonger les demi-vies d'elimination de composes bioactifs |
US6741957B1 (en) | 2000-07-21 | 2004-05-25 | Daimlerchrysler Corporation | Analytical tire model for vehicle durability and ride comfort analysis |
US6818216B2 (en) | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies |
US7054297B1 (en) | 2000-12-28 | 2006-05-30 | Cisco Technology, Inc. | Distribution of packets to high data rate communications devices using multicast protocols |
CN101684158A (zh) | 2001-01-17 | 2010-03-31 | 特鲁比昂药品公司 | 结合域-免疫球蛋白融合蛋白 |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
JP4336771B2 (ja) | 2001-03-09 | 2009-09-30 | モルフォシス アーゲー | 血清アルブミン結合部分 |
DE60237282D1 (de) | 2001-06-28 | 2010-09-23 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
JP2004538324A (ja) | 2001-08-03 | 2004-12-24 | メディカル リサーチ カウンシル | 細胞内抗体 |
FR2829940A1 (fr) | 2001-09-27 | 2003-03-28 | Synt Em | Compositions pour la vectorisation d'anticorps a travers la barriere hematoencephalique et leur utilisation pour le diagnostic ou le traitement des maladies du systeme nerveux central |
KR100599789B1 (ko) | 2001-12-03 | 2006-07-12 | 삼성에스디아이 주식회사 | 방열효율이 향상된 플라즈마 디스플레이 장치 및 그 제조방법 |
WO2003050531A2 (fr) | 2001-12-11 | 2003-06-19 | Algonomics N.V. | Procede d'affichage de boucles de domaines d'immunoglobuline dans differents contextes |
JP2005516939A (ja) | 2001-12-18 | 2005-06-09 | イノジェネティックス・ナムローゼ・フェンノートシャップ | 診断及び治療用途の精製c型肝炎ウイルス外被タンパク質 |
CA2492671C (fr) | 2002-03-22 | 2012-04-17 | Aprogen, Inc. | Anticorps humanise et procede de preparation correspondant |
US7132100B2 (en) * | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
EP1517921B1 (fr) | 2002-06-28 | 2006-06-07 | Domantis Limited | Ligands a specificite double et avec une demi-vie augmentee |
US7004940B2 (en) | 2002-10-10 | 2006-02-28 | Ethicon, Inc. | Devices for performing thermal ablation having movable ultrasound transducers |
EP1565482B1 (fr) | 2002-10-23 | 2014-04-30 | Ludwig Institute for Cancer Research Ltd. | Adn et proteines 3 de type a34 et a33, anticorps associes et methodes de traitement associees |
EP2267032A3 (fr) | 2002-11-08 | 2011-11-09 | Ablynx N.V. | Procédé d'administration de polypeptides thérapeutiques et polypeptides correspondants |
WO2004041862A2 (fr) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Anticorps a domaine unique diriges contre le facteur de necrose tumorale alpha et leurs utilisations |
GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
WO2004060965A2 (fr) | 2002-12-31 | 2004-07-22 | Nektar Therapeutics Al, Corporation | Polymeres a terminaison maleimide hydrolytiquement stables |
EP1587838B1 (fr) | 2003-01-10 | 2015-04-15 | Ablynx N.V. | Polypeptides therapeutiques, leurs homologues, leurs fragments, que l'on utilise dans la modulation de l'agregation plaquettaire |
AU2004242614B2 (en) | 2003-05-30 | 2011-09-22 | Merus N.V. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
US7070786B2 (en) | 2003-06-06 | 2006-07-04 | Centocor, Inc. | RSV proteins, antibodies, compositions, methods and uses |
KR20060034650A (ko) | 2003-06-27 | 2006-04-24 | 바이오렌 인코포레이티드 | 룩-스루 돌연변이 |
ES2315664T3 (es) | 2003-06-30 | 2009-04-01 | Domantis Limited | Anticuerpos de dominio unico (dab) pegilados. |
EP1639465B1 (fr) | 2003-06-30 | 2011-04-06 | Continental Automotive GmbH | Procede permettant de surveiller l'execution d'un programme dans un micro-ordinateur |
CA2535550A1 (fr) | 2003-08-12 | 2005-03-03 | William M. Yarbrough | Traitement de l'acne simple et procede d'utilisation |
EP1512696A1 (fr) | 2003-08-14 | 2005-03-09 | Diatos | Séquences d'acides aminés facilitant la pénétration d'une substance d'intérêt dans les cellules et/ou le noyau |
ES2646560T3 (es) | 2004-01-20 | 2017-12-14 | Merus N.V. | Mezclas de proteínas de unión |
EP1720908A2 (fr) | 2004-02-17 | 2006-11-15 | Absalus, Inc. | Anticorps super-humanises contre les virus respiratoires syncytiaux |
US7207410B2 (en) | 2004-04-29 | 2007-04-24 | Daimlerchrysler Corporation | Apparatus and method for enhanced impact sensing |
JP2008503217A (ja) | 2004-06-18 | 2008-02-07 | アンブレツクス・インコーポレイテツド | 新規抗原結合ポリペプチド及びそれらの使用 |
ES2372503T3 (es) | 2004-07-06 | 2012-01-20 | Bioren, Inc. | Mutagénesis revisada para desarrollar polipéptidos alterados con propiedades potenciadas. |
US7180370B2 (en) | 2004-09-01 | 2007-02-20 | Micron Technology, Inc. | CMOS amplifiers with frequency compensating capacitors |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
US7700720B2 (en) | 2004-09-21 | 2010-04-20 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
BRPI0518151A2 (pt) | 2004-10-13 | 2009-06-16 | Ablynx Nv | polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo |
TW200636064A (en) * | 2004-10-28 | 2006-10-16 | Centocor Inc | Anti-respiratory syncytial virus antibodies, antigens and uses thereof |
CA2585891A1 (fr) | 2004-10-29 | 2006-05-11 | Medimmune, Inc. | Methodes de prevention et de traitement des infections a rsv et des etats pathologiques associes |
CN101133084A (zh) * | 2004-12-02 | 2008-02-27 | 多曼蒂斯有限公司 | 采用白细胞介素-1ⅰ型受体拮抗剂治疗呼吸道疾病的方法 |
JP5011277B2 (ja) * | 2005-04-06 | 2012-08-29 | アイビーシー・ファーマシューティカルズ・インコーポレーテッド | ホモダイマー、ホモテトラマーまたはダイマーのダイマーのからなる安定に連結された複合体を発生させるための方法および使用 |
WO2006110214A2 (fr) | 2005-04-08 | 2006-10-19 | Medimmune, Inc. | Anticorps diriges contre le metapneumovirus du mammifere |
WO2006122787A1 (fr) | 2005-05-18 | 2006-11-23 | Ablynx Nv | Proteines de liaison a l'albumine serique |
CA2666599A1 (fr) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Sequences d'acides amines dirigees contre l'il-6r et polypeptides les contenant utilises pour le traitement de maladies et de troubles associes au signal medie par il-6 |
AU2007293614A1 (en) | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
JP2010505435A (ja) | 2006-10-11 | 2010-02-25 | アブリンクス エン.ヴェー. | 本質的にpHに非依存的に血清タンパク質に結合するアミノ酸配列、それを含む化合物、およびその使用 |
EP2081960B1 (fr) | 2006-10-27 | 2018-06-27 | Ablynx N.V. | Administration intranasale de polypeptides et de protéines |
JP2010511397A (ja) | 2006-12-05 | 2010-04-15 | アブリンクス エン.ヴェー. | 血清タンパク質と結合可能なペプチド |
CA2672944A1 (fr) | 2006-12-22 | 2008-07-03 | Ablynx N.V. | Sequences d'acides amines dirigees contre des chimiokines et polypeptides comprenant celles-ci pour le traitement de maladies et de troubles lies aux chimiokines |
CA2691940C (fr) | 2007-07-03 | 2018-03-06 | Joost Alexander Kolkman | Methodes de fourniture de sequences d'immunoglobuline ameliorees |
BRPI0819656A2 (pt) | 2007-11-27 | 2015-06-23 | Ablynx Nv | Seqüências de aminoácidos contras citocinas heterodiméricas e/ou seus receptores e polipeptídeos compreendendo as mesmas |
EP2096121A1 (fr) | 2008-02-29 | 2009-09-02 | Institut Pasteur Of Shanghai | Peptides antiviraux comprenant des signaux de fixation de lipides et leurs procédés d'utilisation |
SI2285408T1 (sl) * | 2008-06-05 | 2019-02-28 | Ablynx N.V. | Aminokislinska zaporedja usmerjena proti proteinom ovojnicam virusa in polipeptidi, ki zaporedja vsebujejo za zdravljenje virusnih bolezni |
ES2701649T3 (es) | 2009-01-14 | 2019-02-25 | Ablynx Nv | Administración pulmonar de dominios variables individuales de inmunoglobulina y constructos de los mismos |
EP2982690B1 (fr) | 2009-04-30 | 2021-01-27 | Ablynx N.V. | Procede pour la production d'anticorps a domaines |
RU2016103067A (ru) | 2009-06-05 | 2018-11-20 | Аблинкс Нв | Улучшенные аминокислотные последовательности, направленные против респираторно-синцитиального вируса человека (hrsv), и полипептиды, включающие такие последовательности, для профилактики и/или лечения инфекций дыхательных путей |
US9644022B2 (en) | 2009-11-30 | 2017-05-09 | Ablynx N.V. | Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
-
2010
- 2010-06-07 RU RU2016103067A patent/RU2016103067A/ru unknown
- 2010-06-07 SG SG2011084274A patent/SG176095A1/en unknown
- 2010-06-07 WO PCT/EP2010/057921 patent/WO2010139808A2/fr active Application Filing
- 2010-06-07 CA CA2764398A patent/CA2764398A1/fr not_active Abandoned
- 2010-06-07 MX MX2011013013A patent/MX340541B/es active IP Right Grant
- 2010-06-07 EP EP10724497.2A patent/EP2438087B1/fr active Active
- 2010-06-07 US US13/375,357 patent/US8945567B2/en active Active
- 2010-06-07 SI SI201031523T patent/SI2438087T1/sl unknown
- 2010-06-07 PL PL10724497T patent/PL2438087T3/pl unknown
- 2010-06-07 BR BRPI1010830A patent/BRPI1010830A2/pt not_active IP Right Cessation
- 2010-06-07 CN CN201080024764.4A patent/CN102459332B/zh not_active Expired - Fee Related
- 2010-06-07 CN CN201510509040.3A patent/CN105061592A/zh active Pending
- 2010-06-07 RU RU2011153239/10A patent/RU2577134C2/ru active
- 2010-06-07 HU HUE10724497A patent/HUE035773T2/en unknown
- 2010-06-07 LT LTEP10724497.2T patent/LT2438087T/lt unknown
- 2010-06-07 AU AU2010255638A patent/AU2010255638B2/en not_active Ceased
- 2010-06-07 EP EP17162779.7A patent/EP3205670A1/fr not_active Withdrawn
- 2010-06-07 KR KR1020127000199A patent/KR101852204B1/ko active IP Right Grant
- 2010-06-07 NZ NZ597314A patent/NZ597314A/xx not_active IP Right Cessation
- 2010-06-07 JP JP2012513641A patent/JP6081196B2/ja not_active Expired - Fee Related
- 2010-06-07 PT PT107244972T patent/PT2438087T/pt unknown
- 2010-06-07 ES ES10724497.2T patent/ES2643034T3/es active Active
- 2010-06-07 DK DK10724497.2T patent/DK2438087T3/en active
-
2011
- 2011-11-02 ZA ZA2011/08892A patent/ZA201108892B/en unknown
- 2011-11-14 IL IL216341A patent/IL216341A0/en unknown
-
2014
- 2014-09-29 US US14/499,772 patent/US9803001B2/en active Active
-
2017
- 2017-01-18 JP JP2017006690A patent/JP6677659B2/ja not_active Expired - Fee Related
- 2017-08-02 HR HRP20171194TT patent/HRP20171194T1/hr unknown
- 2017-08-08 CY CY20171100847T patent/CY1119265T1/el unknown
- 2017-09-22 US US15/712,247 patent/US11028151B2/en active Active
-
2019
- 2019-03-25 PH PH12019500644A patent/PH12019500644A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2016103067A (ru) | Улучшенные аминокислотные последовательности, направленные против респираторно-синцитиального вируса человека (hrsv), и полипептиды, включающие такие последовательности, для профилактики и/или лечения инфекций дыхательных путей | |
CN107022008B (zh) | 广谱地抑制人类冠状病毒感染的多肽及其应用 | |
CN101415723B (zh) | 具有改良生物学特性的hiv融合抑制肽 | |
CN104072592B (zh) | 对新型冠状病毒HCoV-EMC 2012感染具有抑制作用的多肽及其应用 | |
JP2012528584A5 (fr) | ||
CN113444169B (zh) | 新型冠状病毒的人源单克隆抗体及其应用 | |
ES2349153T3 (es) | Inhibidores del virus de la hepatitis c. | |
BR112021003410A2 (pt) | anticorpos de domínio único anti-bcma, grupo de genes dos ditos anticorpos, polipeptídeo, vetor de expressão, célula hospedeira, receptor de antígeno quimérico, célula t modificada pelo mesmo, composição farmacêutica e usos dos ditos anticorpos | |
JP2008521795A5 (fr) | ||
CN111606993B (zh) | 抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用 | |
KR20120107000A (ko) | 인터페론 유사체 | |
EA017957B1 (ru) | Композиции и способы, ингибирующие грипп | |
JP2022163180A (ja) | 立体構造的に特異的なウイルス免疫原 | |
JP2006506942A5 (fr) | ||
JPH02500517A (ja) | ペプチド化合物 | |
CN107698665B (zh) | 一种抗病毒多肽、编码基因、载体、宿主菌及应用 | |
CN113461810B (zh) | 一种抗新型冠状病毒刺突蛋白的全人源单克隆抗体及其应用 | |
JP2008518622A5 (fr) | ||
KR20150135231A (ko) | 인간 메타뉴모바이러스에 특이적인 인간 항체 또는 그의 항원 결합성 단편 | |
CN108395470B (zh) | 具有抑制登革病毒复制作用的短肽及其应用 | |
Nobiron et al. | Genome and polypeptides characterization of Tellina virus 1 reveals a fifth genetic cluster in the Birnaviridae family | |
CN115109123B (zh) | 一种抗冠状病毒的多肽、其衍生物及其应用 | |
CA3216329A1 (fr) | Nouvelles compositions et nouvelles methodes de traitement d'infections a coronavirus | |
US20080069830A1 (en) | Dna Sequences, Peptides, Antibodies and Vaccines for Prevention and Treatment of Sars | |
CN110234337A (zh) | 中和流感病毒的化合物 |